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BACKGROUND. The link between mucus plugs and airflow obstruction has not been established in chronic severe asthma, and 
the role of eosinophils and their products in mucus plug formation is unknown.
METHODS. In clinical studies, we developed and applied a bronchopulmonary segment–based scoring system to quantify 
mucus plugs on multidetector computed tomography (MDCT) lung scans from 146 subjects with asthma and 22 controls, 
and analyzed relationships among mucus plug scores, forced expiratory volume in 1 second (FEV1), and airway eosinophils. 
Additionally, we used airway mucus gel models to explore whether oxidants generated by eosinophil peroxidase (EPO) oxidize 
cysteine thiol groups to promote mucus plug formation.
RESULTS. Mucus plugs occurred in at least 1 of 20 lung segments in 58% of subjects with asthma and in only 4.5% of controls, 
and the plugs in subjects with asthma persisted in the same segment for years. A high mucus score (plugs in ≥ 4 segments) 
occurred in 67% of subjects with asthma with FEV1 of less than 60% of predicted volume, 19% with FEV1 of 60%–80%, and 
6% with FEV1 greater than 80% (P < 0.001) and was associated with marked increases in sputum eosinophils and EPO. EPO 
catalyzed oxidation of thiocyanate and bromide by H2O2 to generate oxidants that crosslink cysteine thiol groups and stiffen 
thiolated hydrogels.
CONCLUSION. Mucus plugs are a plausible mechanism of chronic airflow obstruction in severe asthma, and EPO-generated 
oxidants may mediate mucus plug formation. We propose an approach for quantifying airway mucus plugging using MDCT 
lung scans and suggest that treating mucus plugs may improve airflow in chronic severe asthma.
TRIAL REGISTRATION. Clinicaltrials.gov NCT01718197, NCT01606826, NCT01750411, NCT01761058, NCT01761630, 
NCT01759186, NCT01716494, and NCT01760915.
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HL109250, U10 HL109168, U10 HL109257, U10 HL109152, and P01 HL107202 and National Center for Advancing Translational 
Sciences grants UL1TR0000427, UL1TR000448, and KL2TR000428.
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mide), and pseudohalides (thiocyanate) 
to generate reactive oxidants that can kill 
pathogens or activate airway cells, includ-
ing mast cells (9). Notably, the product 
of the reaction between thiocyanate and 
H2O2, catalyzed by EPO, is hypothiocya-
nous acid (HOSCN), which is known to 
target thiol groups as a cytotoxic mecha-
nism (10). Recently, we have reported that 
oxidation of cysteine thiol groups — abun-
dant in mucin polymers — is a mechanism 
of mucus gel stiffening in the lung (11), but 
the possibility that EPO promotes mucus 
plug formation by generating oxidants 
that modify mucins is not considered in 
reviews of the pathologic effects of eosin-
ophils in the asthmatic airway (12).
We set out to examine the association 
between airway mucus plugs and airflow 
obstruction in chronic severe asthma and 
to explore whether eosinophils and EPO 
play a pathophysiologic role in the forma-
tion of these plugs. In clinical studies, we 
developed a scoring system to quantify 
mucus plugs in multidetector computed 
tomography (MDCT) scans of the lungs, 
and we used this MDCT-based scoring 
system to determine the relationship between mucus plugs and 
airflow obstruction in subjects with asthma in the SARP. We also 
examined the relationship between measures of mucus plugs and 
measures of airway eosinophils and EPO. In bench studies, we 
explored the pathologic effects of EPO in model systems of the 
airway mucus gel. Specifically, we tested to determine whether 
EPO catalyzes reactions of H2O2 with thiocyanate or bromide to 
generate oxidants that target cysteine thiols to crosslink them or 
that modify thiolated hydrogels to increase elasticity.
Results
Human subjects. MDCT scans of 146 adults with asthma and 22 
healthy controls in the NHLBI SARP were analyzed (Figure 1 and 
Supplemental Table 1; supplemental material available online 
with this article; https://doi.org/10.1172/JCI95693DS1). Among 
the 146 patients with asthma, 66% had disease qualifying as 
severe using American Thoracic Society/European Respiratory 
Society (ATS/ERS) criteria (Table 1) (13), and the prebronchodi-
lator forced expiratory volume in 1 second (FEV1) was less than 
80% of predicted volume in 97 patients (66%) and less than 60% 
of predicted volume in 39 patients (27%).
Airway mucus plugs can be identified and quantified using 
MDCT imaging of the lungs. In preliminary studies, we discovered 
that we could discern mucus plugs in the lungs of subjects with 
asthma using MDCT scans. Specifically, we could identify mucus 
plugs as areas of opacification within the airway lumen, contig-
uous with patent airway lumen across sequential transverse CT 
slices. These opacities were less radiodense than adjacent blood 
vessels, and occlusion of the lumen by these opacities could be 
partial or complete. These mucus plugs were predominantly seen 
Introduction
Despite the prominence of mucus plugs in the pathophysiology of 
airflow obstruction in acute severe (fatal) asthma (1, 2), the role 
of mucus plugs in the pathophysiology of airflow obstruction in 
chronic severe asthma is poorly understood. This limited under-
standing is a barrier to rational treatment of airflow obstruction 
in severe asthma because mucus plugs represent a tractable 
treatment target if they can be shown to be a cause of obstruc-
tion. Developing an understanding of the role of mucus plugs as 
a mechanism of airflow obstruction in chronic severe asthma has 
been held back by methodologic difficulties. To date, imaging 
studies have not systematically examined the airways in patients 
with asthma for intraluminal mucus and studies that have docu-
mented a relationship between mucus pathology and airflow have 
relied on chronic cough and sputum production, a symptom com-
plex known as chronic mucus hypersecretion (CMH) (3, 4). Reli-
ance on CMH symptoms to identify patients with airway mucus 
plugs is problematic because CMH symptoms are often absent 
in patients with chronic obstructive pulmonary disease who have 
pathologically proven mucus plugs (5).
Pathology studies in small numbers of patients with nonfa-
tal asthma reveal airway mucus plugs (6), but the relationship 
between these plugs and airflow obstruction is unclear. In addi-
tion, blood and airway eosinophilia are strongly correlated with 
airflow obstruction in asthma (7, 8), but the relationship between 
eosinophils and mucus plugs is unknown. Eosinophils secrete 
multiple biologically active molecules, including granule proteins, 
lipid mediators, chemotactic peptides, and cytokines. Eosinophil 
peroxidase (EPO) is the most abundant granule protein, and it 
utilizes respiratory burst–derived H2O2, halides (chloride and bro-
Figure 1. Consort diagram of CT substudy. Flow chart shows the number of asthma patients who were 
screened, enrolled, and included in the final analyses.
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each subject. This approach 
generated scores ranging from 
0 to 20 in increments of 0.5. In 
this way, we found that mucus 
plugging was present in at least 
1 of 20 lung segments in 58% 
(85/146) of asthmatic subjects 
and in only 4.5% (1/22) of 
healthy controls (Figure 2E). 
The intraclass correlation coef-
ficient (ICC) for between-rater 
mucus score agreement was 
0.80 (95% CI 0.74 to 0.85) for 
all 168 scans. In addition, the 
within-rater mucus score agree-
ment for a random subset of 14 
scans (3 healthy, 11 asthma) 
that was scored twice by each 
of the 5 radiologists was 0.99 
(95% CI 0.99 to 1.00). Among 
subjects with asthma, the medi-
an value of the mucus score in 
the mucus-present group was 
3.5, and we used this value to 
divide the asthmatic subjects 
into 3 mucus subgroups based 
on mucus score. Asthmatic 
subjects with a mucus score 
of 0 were assigned to the zero 
mucus group, while those with 
mucus scores between 0.5 and 
3.5 were assigned to the low 
mucus group and those with mucus scores between 4 and 20 were 
assigned to the high mucus group (Figure 2F).
Twenty-five asthmatic subjects in SARP 3 also had HRCT 
scans performed previously as part of SARP 1 or SARP 2 (Supple-
mental Table 2). These SARP 1 and SARP 2 scans were obtained 
2 to 9 years prior to the SARP 3 MDCT scans. Two radiologists at 
the University of Wisconsin School of Medicine, Madison, center 
read the 50 scans together to identify and score the mucus plugs. 
In a score-based analysis, we compared mucus scores assigned 
to the first and second scans; mucus scores were unchanged in 7 
subjects (28%), increased in 10 subjects (40%), and decreased in 
8 subjects (32%) over an average of 5.2 years (SD 2.5). We found 
that 90% of subjects with a high mucus score (≥4) on the first 
scan had a high score on the second scan (Figure 2G). In a seg-
ment-based analysis, we compared individual lung segments in 
the first and second scans. Remarkably, 65% of lung segments 
that had a mucus plug on the first scan had a mucus plug in the 
same segment on the second scan. We also found that 80% of 
lung segments with no mucus plug on the first scan had no mucus 
plug in the same segment on the second scan (Figure 2, H and I). 
Persistent presence or absence of mucus plugs from first to sec-
ond scan was seen with similar frequency across all bronchopul-
monary segments (Supplemental Figure 2).
Airway mucus plugs usually occur in the absence of bronchiectasis. 
At the same time that the radiologists scored the scans for mucus 
in subsegmental airways, appearing as focal or branching opaci-
ties (Figure 2, A–C), and usually occurred in the absence of bron-
chial dilatation. Based on these findings, we went on to develop a 
visual scoring system to formally quantify mucus plugs in MDCT 
scans (Figure 2D). Mucus plugs were defined as complete occlu-
sion of a bronchus, irrespective of generation or size. When par-
allel to the scan plane, mucus plugs were recognized as tubular 
densities with or without branching. When oriented obliquely or 
perpendicularly to the scan plane, they were identified as oval 
or rounded opacities seen on sequential slices and differentiat-
ed from blood vessels by their continuity with patent portions 
of the bronchial lumen and their position relative to adjacent 
blood vessels (Supplemental Figure 1 and Supplemental Video 
1). The segments of each lobe were systematically examined for 
the presence or absence of mucus plugs and given a score of 1 or 
0 accordingly (Supplemental Figure 8). The segment scores of 
each lobe were summed to generate a total mucus score for both 
lungs, yielding an aggregate score ranging from 0 to 20. Periph-
eral airways within 2 cm of the diaphragmatic pleura and costal 
pleura were excluded from evaluation, as the small caliber of 
these peripheral airways makes occlusion by mucus difficult to 
ascertain. Five radiologists with subspecialty training in thoracic 
radiology reviewed the MDCT scans. Two radiologists were ran-
domly assigned to score each scan independently, and the scores 
of both raters were averaged to generate the CT mucus score of 
Table 1. Characteristics of subjects with asthma across mucus score categories
Characteristic All Mucus score
Zero Low High
(n = 146) (n = 61) (n = 45) (n = 40)
Mucus score 0.5 (0–4.5) 0 (0) 1.5 (0.5–2.5) 9.5 (6–12)
Mean age (yr)A 46.8 ± 16.0 43.2 ± 15.4 46.7 ± 15.6 52.3 ± 16.3
Female sex, no. (%) 91 (62.3) 43 (70.5) 26 (57.8) 22 (55.0)
Body mass index (kg/m2) 32.7 ± 9.3 34.3 ± 9.9 32.5 ± 10.5 30.7 ± 6.3
Maintenance corticosteroid use, no. (%)
 Inhaled, any dose 141 (96.6) 56 (91.8) 45 (100.0) 40 (100.0)
 Inhaled, high doseA 102 (69.9) 36 (59.0) 30 (66.7) 36 (90.0)
 SystemicA 15 (10.3) 3 (4.9) 3 (6.7) 9 (22.5)
ACTA 18 (14–21) 19 (15–21) 18 (14–22) 16.5 (13–19)
Severe asthma, no. (%)A,B 96 (65.8) 31 (50.8) 29 (64.4) 36 (90.0)
Spirometry
 FEV1 (% of predicted volume)A,C 72.2 ± 20.6 81.0 ± 16.2 74.5 ± 20.8 56.1 ± 17.4
Sputum eosinophil count (%)A,C,D 0.7 (0, 4.4) 0.2 (0, 0.9) 0.5 (0.2, 1.6) 7.3 (1.5, 21.4)
Blood eosinophil count (×106/l)A,C,E 306 ± 276 209 ± 153 309 ± 282 459 ± 349
FeNO (ppm)A,F 22 (12, 33) 18 (10, 27) 24 (13, 38) 28 (19, 40)
CMH, no. (%)G 41 (34.0) 18 (29.5) 10 (22.2) 13 (32.5)
Bronchiectasis on CT, no. (%) 29 (19.9) 7 (11.5) 11 (24.4) 11 (27.5)
Data reported as mean ± SD or median (IQR). Zero represents the mucus absent group (mucus score = 0). Low 
represents the group with mucus scores 0.5–3.5, and high represents the group with mucus scores of 4 or more, 
based on the median score of 3.5 in the mucus present group. AP < 0.05 for comparison of zero and high scores. 
BThe classification of asthma severity was determined using ATS/ERS criteria. CP < 0.05 for comparison of low 
and high scores. DSputum cell counts were not available in 40 subjects due to ineligibility for sputum induction or 
because the induced sputum did not meet quality metrics. EBlood measurements were not available for 2 subjects. 
FFeNO was not measured in 4 subjects. GDefined by WHO. Questionnaire data are missing in 25 patients (see 
Supplemental Methods).
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low or zero mucus score (Table 1) (P = 0.07). The prevalence of 
bronchiectasis or mucus plugging did not differ among the 5 lung 
lobes (Figure 3B), but the prevalence of mucus plugging was 4 to 
5 times higher than that of bronchiectasis in any given lung lobe 
(Figure 3B). Bronchiectasis was weakly but significantly associat-
ed with mucus plugging at a lobar level — mainly because most 
lobes with bronchiectasis had mucus plugging (Figure 3C) — but 
relatively few lobes with mucus plugging also had bronchiectasis 
plugging, they also systematically examined each of the 5 lung 
lobes for the presence or absence of bronchiectasis, defined as a 
bronchoarterial ratio of greater than 1.5. This approach generated 
a mean bronchiectasis score ranging from 0 to 5 as well as a binary 
outcome for presence or absence of bronchiectasis. We found that 
only 20% of the subjects with asthma had bronchiectasis (Table 
1 and Figure 3A) and that bronchiectasis tended to be more fre-
quent in subjects with a high mucus score than in those with a 
Figure 2. Development and distribution 
of the CT mucus score in asthma patients 
and healthy subjects. (A) Mucus plug with 
branching (yellow arrow) seen in longitudinal 
section is identified as a tubular opacification 
(frontal plane). (B) Mucus plug (yellow arrow) 
with extensive branching seen in longitudinal 
section (transverse plane). (C) Mucus plug (yel-
low arrow) seen in cross-section is identified 
as rounded opacification (transverse plane). 
(D) Schematic representation showing how 
MDCTs were evaluated to generate the mucus 
score. Airways within the 2 cm peripheral zone 
on MDCT (shown in red) or airways that were 
partially occluded were excluded from assess-
ment. Mucus plugs were defined as complete 
occlusion of an airway. Each bronchopulmo-
nary segment was assessed and scored for 
the presence or absence of 1 or more mucus 
plug(s), and the segment scores were summed 
to generate the mucus score. (E) Segment 
score in healthy patients and patients with 
asthma. (F) Frequency distribution of segment 
score in patients with asthma. The color code 
above the x axis defines 3 mucus groups: green 
indicates patients with a mucus score of 0 
(zero mucus group); blue indicates patients 
with mucus scores between 0.5 and 3.5 (low 
mucus group); and orange indicates patients 
with mucus scores of 4.0 or more (high mucus 
group). (G) Sankey bar graph showing the 
change in mucus score in 25 asthmatic sub-
jects from SARP 1/2 to SARP 3. (H) Pie chart 
of segments with mucus plugging on baseline 
scan; 65% of these segments had mucus plug-
ging on rescan. Pie chart of segments with no 
mucus plugging on baseline scan; 79% of these 
segments had no mucus plugging on rescan. 
(I) MDCTs showing a mucus plug occluding the 
airway (yellow arrow) of the right lower lobe in 
2010 and a mucus plug occluding the same air-
way, visible more proximally (yellow arrow) and 
branching into the adjacent airway, in 2013. 
***P < 0.001, unequal variances t test.
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analyses (Table 2). The mean FEV1 was 25% lower in the high 
mucus subgroup than in the zero mucus subgroup (Table 1 and 
Figure 4A), and the values for the FVC and FEV1/FVC ratio were 
also significantly decreased in the high mucus subgroup (Figure 
4A). In addition, 66.7% of subjects with a prebronchodilator FEV1 
of less than 60% of predicted volume had a high mucus score 
compared with 19% of subjects with FEV1 60%–80% of predict-
ed volume and 6.1% of subjects with FEV1 greater than 80% of 
predicted volume (Figure 4B). The low FVC in subjects with high 
mucus scores suggested air trapping in these subjects (14), and we 
confirmed this in a subset of subjects (n = 43) who had undergone 
body plethysmography as part of their baseline characterization 
studies. Specifically, we found that the ratio of residual volume to 
total lung capacity (RV/TLC) was also higher in the high mucus 
group than in the low mucus group, indicating more air trapping in 
the high mucus group (P = 0.04) (Supplemental Figure 3).
We next explored whether the strong association between 
MDCT mucus scores and abnormal lung function is reflected in 
abnormalities in other asthma outcomes. We found that, com-
pared with the zero mucus group, the high mucus group had 
higher asthma medication requirements, worse asthma control 
test (ACT) scores, and were more frequently classified as having 
(Figure 3D). In an analysis of the 25 subjects with repeat MDCT 
scans for comparison, there was a low prevalence of mucus plug-
ging on initial CT scan (2 out of 25 subjects) and the prevalence 
was unchanged in the second scan. In a lobe-based analysis, we 
compared individual lung lobes in the first and second scans and 
found that 83% of lung lobes (5/6 lobes) that showed bronchiecta-
sis on the first scan showed bronchiectasis in the same lobe on the 
second scan. We also found that 99% of lung lobes (118/119 lobes) 
with no bronchiectasis on the first scan had no bronchiectasis in 
the same lobe on the second scan (Figure 3E).
Airway mucus plugs strongly associate with measures of airflow 
obstruction in asthma. To determine the association between air-
way mucus plugs and airflow obstruction in the subjects with asth-
ma, we examined the relationship between the mucus score and 
measures of airflow obstruction by spirometry. We found that the 
mucus scores were inversely correlated with prebronchodilator 
measures of FEV1 percentage of predicted volume (Spearman’s 
rho = –0.51, P < 0.001), forced vital capacity (FVC) percentage 
of predicted volume (Spearman’s rho = –0.32, P < 0.001), and 
FEV1/FVC ratio of predicted volume (Spearman’s rho = –0.54, P < 
0.001). These associations remained significant after controlling 
for age, sex, and measures of airway wall thickness in regression 
Figure 3. Relationship between bronchiectasis and mucus plugging. (A) Frequency distribution of bronchiectasis score in patients with asthma. (B) Prev-
alence of bronchiectasis versus mucus plugging in each lung lobe. The prevalence of mucus plugging is 4 to 5 times higher than the prevalence of bron-
chiectasis in each lobe. There is no significant difference in prevalence of bronchiectasis or mucus plugging across individual lobes. (C) Mucus plugging is 
present in 35% of lobes that have no bronchiectasis present and 58% of lobes that have bronchiectasis present (P = 0.001). (D) Bronchiectasis is present in 
5% of lobes that have no mucus plugging present and only 12% of segments that have mucus plugging present (P = 0.001). There is a positive association 
between mucus plugging and bronchiectasis, but mucus plugging usually occurs in the absence of bronchiectasis. (E) Pie charts illustrating the prevalence 
of bronchiectasis in repeat CT scans in 25 patients. The data show that 83% of lung lobes with mucus plugs visible on the first scan had mucus plugging 
visible on the second scan; in contrast, 99% of lung lobes with no mucus plugs visible in the first scan also had no mucus plugs visible on the second scan.
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severe asthma (Table 1 and Supplemental Methods). In addition, 
the percentage of patients in the high mucus group who had expe-
rienced at least 1 asthma exacerbation in the previous year was 
higher than in the zero mucus group, but this difference was not 
statistically significant (Supplemental Table 3). Notably, only 2 
asthma subjects in the cohort met criteria for a diagnosis of aller-
gic bronchopulmonary aspergillosis (ABPA) (15), and both had 
mucus scores in the low (0.5–3.5) range (Supplemental Table 3); 
sensitivity to other molds and aeroallergens did not differ signifi-
cantly among mucus groups (Supplemental Table 4).
Influence of airway mucus plugs on treatment responses to β adren-
ergic agonists and systemic corticosteroids. To explore whether airway 
mucus plugs influence treatment responses, we first examined 
responses to inhaled albuterol (540–720 mcg) using data from max-
imum bronchodilator reversibility testing (MBRT). Although there 
was no significant difference in the absolute change in FEV1 follow-
ing albuterol treatment among the 3 mucus groups (Figure 5A), we 
found that the mean postbronchodilator FEV1 in the high mucus 
group was 23% lower than in the zero mucus group (Figure 5B) and 
that a persistently low FEV1 (FEV1 < 80% of predicted volume) fol-
lowing MBRT was common in subjects with a high mucus score, but 
uncommon in subjects with a zero mucus score (Figure 5C).
We next examined responses to intramuscular triamcino-
lone acetonide (40 mg) using data from systemic corticosteroid 
responsiveness testing (SCRT). Although there was no signifi-
cant difference in the absolute change in FEV1 following corti-
costeroid treatment among the 3 mucus groups (Figure 5D), we 
found that the mean poststeroid FEV1 was 20% lower in the high 
mucus group than in the zero mucus group (Figure 5E). As with 
the data for albuterol treatment, we noted that a persistently low 
FEV1 following SCRT was common in subjects with a high mucus 
score, but uncommon in subjects with a zero mucus score (Figure 
5F). In addition, we found that the CT mucus score was an inde-
pendent predictor of residual abnormalities in FEV1 after sys-
temic corticosteroid administration in logistic regression models 
(Supplemental Figure 4).
Finally, we examined responses to combined treatment with 
albuterol and systemic corticosteroid among the 3 mucus sub-
groups. Here, we found that the absolute change in FEV1 following 
MBRT and SCRT was significantly higher in the high mucus group 
than in the zero and low mucus groups (Figure 5G), but the mean 
postbronchodilator/poststeroid FEV1 was still significantly lower 
in the high mucus group than in the zero mucus group (Figure 5H). 
Half of the subjects with high mucus scores had persistently low 
Table 2. Relationship among mucus score, spirometry measures, and sputum eosinophils (adjusted for covariates)
Asthma outcomeA Unadjusted Model 1 Model 2 Model 3 Model 4
FEV1, % of predicted volume –2.2 (–2.8, –1.5)  
R2 = 0.24, P < 0.001
–1.9 (–2.6, –1.3)  
R2 = 0.28, P < 0.001 
–1.9 (–2.5, –1.2)  
R2 = 0.34, P < 0.001
–1.5 (–2.2, 0.8)  
R2= 0.38, P < 0.001
–13 (–21.5, –4.8)  
R2 = 0.41, P = 0.001
FVC, % of predicted volume –1.3 (–1.8 to –0.7)  
R2 = 0.11, P < 0.001
–0.9 (–1.5, –0.3)  
R2 = 0.25, P = 0.002
–0.9 (–1.4, –0.3)  
R2 = 0.27, P = 0.003
–0.7 (–1.3, –0.04)  
R2 = 0.29, P = 0.04
–6.5 (–14.4, 1.4)  
R2 = 0.30, P = 0.1
FEV1/FVC –1.4 (–1.8 –1.0)  
R2 = 0.26, P < 0.001
–1.5 (–1.9, –1.1)  
R2 = 0.29, P < 0.001
–1.4 (–1.8, –1.0)  
R2 = 0.34, P < 0.001
–1.3 (–1.7, –0.8)  
R2 = 0.38, P < 0.001
–8.0 (–13, –2.7)  
R2 = 0.41, P = 0.003
Sputum eosinophils %B 0.96 (0.7, 1.3)  
R2 = 0.28, P < 0.001
0.93 (0.6, 1.3)  
R2 = 0.29, P < 0.001
0.94 (0.6, 1.3)  
R2 = 0.30, P < 0.001
ALinear regression model reports β coefficient (95% CI) for asthma outcomes. Predictor variable is mucus score ranging from 0 to 20. Model 1 adjusts for 
the covariate of age at screening. Model 2 adjusts for the covariates of age and sex. Model 3 adjusts for the covariates of age, sex, and wall thickness 
percentage. Model 4 adjusts for the covariates of age, sex, and an interaction term for mucus score minus wall thickness percentage. BSputum data was 
missing in 40 patients.
Figure 4. Mucus plugging is associated with low lung function. (A) 
Spirometric measures of lung function (FEV1, FVC, and FEV1/FVC) in the 
subjects with a high mucus score were significantly lower than in subjects 
with a low mucus score and subjects with a zero mucus score. (B) High 
mucus plug scores were much more common in patients with severe 
airflow obstruction. ***P < 0.001; **P < 0.01, Kruskal-Wallis test with 
Dunn’s correction.
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FEV1 following SCRT and MBRT, whereas only a small subgroup 
of subjects with zero mucus scores had persistently low FEV1 (Fig-
ure 5I). Thus, aggressive treatment with β adrenergic agonists and 
corticosteroids frequently does not normalize lung function in 
subjects with airway mucus plugs, and additional treatments need 
to be considered for these subjects.
Symptoms of CMH are neither sensitive nor specific for mucus 
plugs. To determine whether subjects with asthma could have 
mucus plugs without CMH symptoms, we examined the frequen-
cy of symptoms of CMH in the 3 mucus plug subgroups. Among 
121 subjects who completed the cough and sputum questionnaire, 
41 (34%) satisfied WHO criteria for CMH (cough and sputum pro-
duction on most days for at least 3 months a year for at least 2 con-
secutive years) (16). We found that 16 (40%) subjects in the high 
mucus group did not have symptoms of CMH (Table 1). Converse-
ly, we found that 18 (30%) subjects in the zero mucus group had 
symptoms of CMH. Although the subgroup of subjects with CMH 
did not have higher mucus scores than subjects without CMH, the 
subjects with CMH were characterized by other clinical differenc-
es, such as older age, higher BMI, and evidence of more severe 
asthma (Supplemental Table 5). Interestingly, subjects with CMH 
did not differ from subjects without CMH in blood or sputum cell 
differentials or in sputum cell gene expression of cytokines or 
mucin genes (Supplemental Table 5).
Mucus plugging shown on MDCT scans is associated with airway 
eosinophilia. To explore whether eosinophils play a pathophysio-
logic role in the formation of mucus plugs, we analyzed multiple 
outcomes related to type 2 inflammation in blood and biospec-
imens in the 3 mucus subgroups. We found that eosinophils in 
blood and sputum and nitric oxide levels in exhaled breath were 
Figure 5. Persistent airflow obstruction is 
seen in subjects with high mucus scores after 
treatment with bronchodilators and steroids. 
(A) The absolute change in FEV1 percentage of 
predicted volume after bronchodilator treat-
ment did not differ across mucus groups. (B) 
The FEV1 percentage of predicted volume after 
bronchodilator treatment was significantly 
lower in the high mucus group than in the zero 
mucus group. (C) Residual postbronchodilator 
abnormalities in FEV1 (FEV1 < 80%) occur 
more commonly in subjects with a high mucus 
score than in those with a zero mucus score. 
(D) The absolute change in FEV1 percentage of 
predicted volume after steroid treatment did 
not differ across mucus groups. (E) The FEV1 
percentage of predicted volume after steroid 
treatment was significantly lower in the high 
and low mucus groups than in the zero mucus 
group. (F) Residual poststeroid abnormalities in 
FEV1 (FEV1 < 80%) occurred more commonly in 
subjects with a high mucus score than in those 
with a zero mucus score. (G) The absolute 
change in FEV1 percentage of predicted volume 
after bronchodilator and steroid treatment was 
significantly higher in the high mucus group 
than in the zero mucus group. (H) The FEV1 
percentage of predicted volume after broncho-
dilator and steroid treatment was significantly 
lower in the high mucus group than in the zero 
mucus group. (I) Residual postbronchodilator 
and poststeroid abnormalities in FEV1 (FEV1 
< 80%) occurred more commonly in subjects 
with a high mucus score than in those with a 
zero mucus score. ***P < 0.001; **P < 0.01, 
Kruskal-Wallis test with Dunn’s correction.
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groups. We found that gene expression for IL-13 and IL-5 in spu-
tum cells was significantly higher in the high mucus group than in 
the low and zero mucus groups and remained high following sys-
temic corticosteroid treatment (Figure 6, C and D). In addition, we 
found that the ratio of gene expression of MUC5AC to MUC5B in 
sputum cells was significantly higher in the high mucus group than 
in the low and zero mucus groups and normalized following sys-
temic corticosteroid treatment (Figure 6E). The presteroid pattern 
of a high expression of MUC5AC relative to MUC5B in the high 
mucus group is typical of the activation effects of IL-13 on mucin 
expression by airway epithelial cells (17).
EPO generates oxidants that crosslink cysteines and stiffen thi-
olated hydrogels. We have recently shown that neutrophil-driven 
oxidation crosslinks cysteine-rich mucin polymers to stiffen air-
way mucus gels in cystic fibrosis (11), and we explored here wheth-
er eosinophil-driven oxidation might be a mechanism of mucus 
significantly higher in the high mucus group than in the low and 
zero mucus groups (Table 1 and Figure 6A). Among subjects with 
high mucus scores, 71% had sputum eosinophilia (sputum eosino-
phils > 2%) and 66% had systemic eosinophilia (blood eosinophils 
> 300 × 10–9/l). Airway mucus scores were positively and signifi-
cantly associated with the sputum eosinophils (Spearman’s rho = 
0.51, P < 0.001) (Figure 6B), and this relationship remained signif-
icant in linear regression models that controlled for age, sex, and 
wall thickness percentage (Table 2). In addition, sputum eosino-
phils and fractional exhaled nitric oxide (FeNO) remained high in 
many subjects with high mucus scores following systemic cortico-
steroid treatment, and the CT mucus score was an independent 
predictor of residual sputum and elevated FeNO after systemic 
corticosteroids in regression models (Supplemental Figure 5).
We next explored gene-expression outcomes related to type 2 
inflammation and mucins in sputum cells from the 3 mucus sub-
Figure 6. High mucus score is associated with markers of type 2 inflam-
mation. (A) Sputum eosinophil percentage is significantly increased in 
patients with a high mucus score and remains significantly increased in 
patients with a high mucus score following treatment with intramuscular 
steroid (triamcinolone acetonide). (B) The sputum eosinophil percentage 
is significantly and positively associated with the mucus score. (C) Gene 
expression for IL-13 is significantly increased in patients with a high mucus 
score and remains significantly increased in patients with a high mucus 
score following treatment with intramuscular steroid. (D) Gene expres-
sion for IL-5 is significantly increased in patients with a high mucus score 
and remains significantly increased in patients with a high mucus score 
following treatment with intramuscular steroid. (E) The MUC5AC/MUC5B 
ratio is significantly increased in patients with high mucus scores. ***P < 
0.001; **P < 0.01; *P < 0.05. P values were determined by Kruskal-Wallis 
test with Dunn’s correction unless otherwise indicated.
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airway mucus gel. The first model was a boron-dipyrromethene–
labeled (BODIPY-labeled) cysteine reagent that quenches when 
cysteine forms its oxidized disulfide product (cystine) (Figure 
7C). The second model system was a synthetic thiolated hyal-
uronan reagent that forms a hydrogel and increases its elastici-
ty when oxidized (18). EPO catalyzes the oxidation of chloride, 
bromide, and thiocyanate by H2O2 to hypochlorous acid (HOCl), 
hypobromous acid (HOBr), and HOSCN, respectively. Specificity 
constants indicate that thiocyanate is a major substrate for EPO, 
and HOSCN is known to be a more thiol-specific oxidant than 
HOBr or HOCl (10). To test whether EPO generates HOSCN that 
catalyzes conversion of cysteine to its oxidized disulfide product 
plug formation in asthma. The activity of EPO can generate 
products that target thiol groups as a cytotoxic mechanism (10), 
and we considered the possibility that EPO-generated products 
oxidize the thiol groups of cysteine residues in mucin polymers 
to cause mucus plugs to form. As a first step, we measured EPO 
in sputum from the zero and high mucus subgroups and healthy 
controls. We found a positive correlation between sputum EPO 
levels and sputum eosinophils (Spearman’s rho = 0.59, P < 0.001) 
(Figure 7A) and also found that EPO levels in the high mucus plug 
group were markedly higher than in the zero mucus group and 
in healthy controls (Figure 7B). We next tested the effect of EPO 
activity on cysteine crosslinking using 2 model systems of the 
Figure 7. Eosinophil products are associated with mucus plugging. (A) The sputum eosinophil percentage is positively associated with sputum EPO levels. 
(B) Sputum EPO is higher in the high mucus group (n = 32) than in the zero mucus group (n = 45) and healthy controls (n = 39). (C) Schematic representa-
tion of the cysteine-linking assay: 2 cysteines labeled with BODIPY FL fluoresce green as monomers but quench when oxidized to form a cystine dimer. (D) 
Effect of EPO and H2O2 on cysteine crosslinking in the presence of chloride, bromide, or thiocyanate. Cysteines do not undergo significant crosslinking with 
EPO and H2O2 in the presence of chloride, but cysteines exposed to EPO and H2O2 in the presence of bromide, and especially thiocyanate, undergo much 
more oxidation and crosslinking. RFU, relative fluorescent units. (E) Effect of HOSCN, the product of EPO-catalyzed reaction of H2O2 and thiocyanate, on 
the viscoelastic properties of a thiolated hydrogel measured by rheology. A large increase in the elastic modulus (G′) of the hydrogel was seen following 
exposure of the hydrogel to EPO with H2O2 and KSCN. There was no significant increase in G′ in the hydrogel in the absence of EPO. (F) Conceptual model 
for how type 2 inflammation promotes airway mucus plug formation in asthma. IL-13 increases thiocyanate transfer into the airway lumen. Once in the 
airway lumen, it is oxidized by H2O2 to form HOSCN, a reaction catalyzed by EPO. HOSCN targets cysteine thiol groups in secreted mucin polymers to gener-
ate covalent disulfide mucin crosslinks. Crosslinked mucins have a high elasticity that decreases their clearance by the mucociliary escalator and results in 
mucus plug formation. The data are presented as mean ± SD of 3 replicates in D and 4 replicates in E. *P < 0.05; **P < 0.01; †P < 0.01; ‡P < 0.001. P value 
was determined by ANOVA with Bonferroni’s correction.
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in specific airways is not anatomical because bronchiectasis was 
an uncommon finding in our patients and mucus plugs usually 
occurred in the absence of bronchiectasis. We consider it unlikely 
that the same mucus plug is long lived for years in an airway and 
more likely that mucus plugs repeatedly form and reform in sus-
ceptible bronchopulmonary segments. We speculate that these 
segments are susceptible to mucus plugging because they have 
heightened type 2 inflammation based on associations we found 
between high mucus plug scores and increased sputum measures 
of eosinophils and type 2 cytokines.
The protocol followed by participants in SARP included a 
maximal bronchodilator reversibility test and a systemic cortico-
steroid response test. Data from these tests allowed us to compre-
hensively assess the effect of mucus plugs on treatment responses 
to inhaled albuterol and systemic triamcinolone. We discovered 
that subjects in the high mucus subgroup who had marked reduc-
tion in FEV1 and FVC pretreatment frequently did not normalize 
their FEV1 or FVC after treatment. One possibility is that mucus 
plugs are not substantially affected by these treatments and that 
specific mucoactive drugs will need to be used in these subjects in 
order to normalize their lung function. The CT mucus score that 
we describe here will be invaluable in identifying subjects for pre-
cision clinical trials of this approach. In this regard, it is important 
that we discovered that symptoms of CMH are neither sensitive 
nor specific for the mucus plug phenotype we uncovered here, per-
haps because the mucus plugs occur in subsegmental airways that 
lack large numbers of cough receptors (19–21). We also show that 
the clinical and airway inflammation features of the CMH pheno-
type are different from the features of the mucus plug phenotype. 
Thus, not all mucus phenotypes in asthma are the same, and we 
demonstrate the unique ability of MDCT lung imaging to identify 
patients with a mucus plug phenotype.
Airway mucus in health is normally a lightly crosslinked gel 
that does not form plugs (22, 23), and it is puzzling why mucus 
plugs were so common in our subjects. Cellular and molecular 
analyses of airway biospecimens from subjects with mucus plugs 
and controls provided valuable clues about the mechanism of 
mucus plug formation. The main clue came from analysis of spu-
tum leukocytes in which we found that subjects with mucus plugs 
had marked sputum eosinophilia. They also had marked increas-
es in sputum cell gene expression for type 2 cytokines, such as 
IL-5 and IL-13, and a relative increase in MUC5AC gene expres-
sion over MUC5B. This latter finding is relevant because cysteine 
domains are more prevalent in MUC5AC than in MUC5B (24), and 
we have previously shown that neutrophil-driven oxidation in the 
airways in cystic fibrosis can crosslink cysteine-rich mucin poly-
mers to stiffen the mucus gel (11). In our studies, we found strong 
evidence that eosinophil-driven oxidation mediates mucus plug 
formation in asthma. First, we found that EPO levels were high 
in subjects with mucus plugs and that EPO showed activities in 
model systems of the airway mucus gel that promoted increased 
elasticity of the gels. Specifically, we found that EPO catalyzed 
reactions of H2O2 with bromide and thiocyanate to generate oxi-
dants (HOBr and HOSCN, respectively) that could convert cyste-
ines to their oxidized disulfide products (cystines). We also found 
that HOSCN could oxidize a thiolated hydrogel to convert it from 
a liquid form to a solid form. HOSCN could be expected to form in 
(cystine), we exposed BODIPY-labeled cysteine to EPO in the 
presence of H2O2 and either chloride (NaCl), bromide (NaBr), 
or thiocyanate (KSCN). We found no significant cystine dimer 
formation when BODIPY-labeled cysteine was exposed to EPO, 
H2O2, and chloride, but dimer formation was significantly greater 
when the BODIPY-labeled cysteine was exposed to EPO, H2O2, 
and bromide and was greatest when the BODIPY-labeled cys-
teine was exposed to EPO, H2O2, and thiocyanate (Figure 7D). 
Thus, HOBr and HOSCN can oxidize cysteines, but HOSCN 
is more potent and HOCl has no effect in this system. We next 
tested to determine whether HOSCN can crosslink the thiolated 
hyaluronan reagent. Here, we used a cone and plate rheometer 
to measure changes in the elasticity of the hydrogel under dif-
ferent conditions. We found that the combination of EPO, H2O2, 
and thiocyanate markedly increased the elasticity of the thiolated 
hyaluronan gel and that EPO was required for this effect (Figure 
7E). Thus, HOSCN can convert a thiolated hydrogel from a liquid 
form to a solid form, leading us to propose that HOSCN is an oxi-
dant product of EPO activity that may mediate mucus plug for-
mation in asthma (Figure 7F).
Nearly 60% of the subjects in the high mucus subgroup had 
reported an asthma exacerbation in the previous year, but near-
ly 50% of the zero mucus group had also experienced an asthma 
exacerbation in that time frame. The 20% increase in exacerba-
tions in the high versus zero mucus groups did not reach statis-
tical significance in our cohort, and larger studies than ours will 
be needed to more fully explore the relationship between airway 
mucus plugs and exacerbations in severe asthma.
Discussion
Among the asthmatic subjects we studied, 66% had physiologic 
evidence of airflow obstruction and 27% had severe obstruc-
tion. Using a method of quantifying mucus plugs based on visu-
al assessment of MDCT scans by experienced chest radiologists, 
we found a strong inverse relationship between the MDCT mucus 
score and FEV1 values. We also found that the majority of subjects 
with severe obstruction had at least 4 bronchial subsegments with 
1 or more airways completely occluded with mucus. Some of these 
subjects had mucus plugs in more than half of their bronchial sub-
segments. Although strong associations do not prove causality, 
we propose that the association between mucus plugs and airflow 
obstruction in these subjects with asthma is causal because mucus 
plugs that completely occlude subsegmental airways will cause 
regional airflow obstruction at a minimum and more widespread 
airflow limitation when present in multiple bronchopulmonary 
segments. Indeed, we found that subjects with high mucus scores 
had air trapping, as evidenced by low FVC and high RV. Air trap-
ping is recognized as a prominent characteristic of severe forms of 
asthma, but the mechanisms have not been well understood (14). 
The mucus plugs we identify here represent a plausible mecha-
nism of air trapping in at least some of the subjects who have this 
physiologic abnormality.
Although the mucus plugs were heterogeneously distribut-
ed in the 20 bronchopulmonary segments among subjects, we 
found that they tended to be found in the same bronchopulmona-
ry segment within individual subjects over long periods of time. 
The mechanism of this susceptibility to mucus plug formation 
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was stopped and the last maneuver was taken to be the highest achiev-
able measure. No more than 8 puffs of albuterol were administered as 
part of the MBRT procedure. MBRT was measured on baseline visits 2 
and 3 (Supplemental Figure 6).
SCRT. Subjects were given an intramuscular injection of triamcin-
olone acetonide (40 mg) following complete characterization on visit 
2. Repeat characterization after steroid injection (excluding MDCT) 
was carried out on visit 3 (2 to 4 weeks later) (Supplemental Figure 6).
MDCT protocol and analysis. Details about the MDCT parame-
ters are provided in Supplemental Tables 6 and 7. A standard window 
width of 1200 HU and level of 600 HU were used for visual bron-
chial wall evaluation (28). Radiologists were blinded to the clinical 
characteristics of the subjects. Quantitative measures of airway wall 
thickness and lumen area were generated using Apollo 1.2 (VIDA 
Diagnostics) (Supplemental Figure 7) and further described in the 
Supplemental Methods.
Sputum induction, cell counts, and gene expression. Sputum induc-
tion was performed on visits 2 and 3 (Supplemental Figure 6). For safe-
ty, induced sputum was only collected from subjects whose FEV1 was 
more than 50% of predicted volume after albuterol pretreatment (360 
ug). Total and differential cell counts and sputum cell gene expression 
were quantified at a centralized laboratory using methods previously 
described (29–31). The primers and probes used for measurement of 
gene expression are provided in Supplemental Table 8.
EPO assay. Human EPO was measured by sandwich ELISA in 
supernatant collected by sputum induction methods adopted from 
the NHLBI Asthma Clinical Research Network (32). Samples were 
diluted 1:50 in assay diluent, per manufacturer-recommended pro-
tocols (Diagnostic Development). The detection limit of the assay is 
less than 0.2 ng/ml.
Cysteine crosslinking assay. To explore cystine formation generat-
ed by EPO with H2O2 in the presence of chloride, bromide, or thiocy-
anate, BODIPY FL L-cysteine was generated from 800 mM BODIPY 
FL L-cystine (Thermo Fisher Scientific) in Tyrode’s Salts by reduction 
with one-quarter volume packed TCEP-Gel (Thermo Fisher Scientif-
ic) for 1 hour at 25°C. The reaction yielded an 8- to 10-fold increase in 
fluorescence at 490 nm/520 nm excitation/emission (Ex/Em). This 
reagent was diluted in 100 μl Tyrode’s Salts to 4 μM with and without 
PMA (100 ng) in 96-well round-bottom nontreated black polystyrene 
plates (Corning Costar). The decrease in fluorescence at 490 nm/520 
nm Ex/Em was monitored over 90 minutes at 37°C on a Synergy H1 
plate reader (BioTek Instruments) with the addition of EPO with H2O2 
and a (pseudo)halide. The plates were sealed with optical adhesive 
film (Applied Biosystems) to prevent evaporation. The quenching of 
BODIPY fluorescence by eosinophil stimulation was shown to return 
to baseline values by the addition of DTT to the wells at the end of 
incubation, indicating that this effect was due to reformation of cys-
tine and not destruction or bleaching of the fluorophore.
Thiolated hydrogel. HOSCN, the product of the EPO-catalyzed 
reaction of H2O2 with potassium thiocyanate (KSCN), was examined 
for its ability to increase the elasticity of thiolated hyaluronic acid. 
KSCN (2 mM) and H2O2 (2 mM) were incubated for 15 minutes at 25°C 
with or without EPO (6 nM) in a 0.5% solution of thiolated hyaluronic 
acid/phosphate buffer pH 7.4 (Glycosil, Ascendance Bio). The elastic 
moduli (G′) for the solutions were then measured on a cone and plate 
rheometer (TA Instruments) oscillating at 1 Hz and 5% strain. The gel 
solution without reactants was also assessed for background elasticity.
the lumen of asthmatic airways because of the pleotropic effects 
of type 2 cytokines, which included effects that caused eosinophil 
accumulation (23), hydrogen peroxide production (25), and pen-
drin upregulation (26). Pendrin is relevant because it mediates the 
exchange of thiocyanate across airway epithelial cells (27). Taken 
together, our data lead us to propose that mucus plugs form in the 
airways of patients with asthma because of multiple consequences 
of airway type 2 inflammation that lead to mucin-eosinophil inter-
actions that promote mucus plugs (Figure 7F).
In summary, our data provide strong evidence that airway 
mucus plugs are common in chronic severe asthma, persist over 
time, and contribute to mechanisms of chronic airflow obstruction. 
We also provide data to implicate EPO as a key mediator in gen-
erating thiol-specific oxidants that oxidize mucins to cause mucus 
plugs to form. We propose that the detection of mucus plugs in the 
lung using MDCT lung scans can serve as a biomarker of disease 
severity in the airways of patients with asthma and can be indic-
ative of outcome for clinical trials that could determine wheth-
er mucolytics or inhibitors of type 2 inflammation can decrease 
mucus plugs to improve airflow in chronic severe asthma.
Methods
Subjects. Adult asthma subjects were recruited as part of the SARP 3 
cohort. The SARP 3 protocol includes 3 baseline visits in which asthma 
subjects undergo detailed characterization, including sputum ques-
tionnaires, MBRT, a systemic corticosteroid responsiveness test, and 
an optional MDCT scan of the lungs (Supplemental Figure 6). Data 
reported here are from subjects that had MDCT scans as part of their 
baseline characterization. CT was not repeated after steroid injection. 
Healthy subjects for MDCT scans were recruited at a single center 
(Washington University), and subjects for sputum cell analyses were 
recruited from all SARP 3 centers (Supplemental Table 1). Twenty- 
five asthma subjects who had MDCT scans as part of the SARP 3 pro-
tocol also had MDCT scans available from their participation in SARP 
1 or SARP 2 protocols. These subjects were enrolled at 3 sites: Uni-
versity of Pittsburgh, University of Wisconsin, and Washington Uni-
versity (Supplemental Table 2). Forty-three asthma subjects who had 
MDCT scans as part of the SARP 3 protocol also had plethysmography 
performed. These subjects were enrolled at the University of Wiscon-
sin (Supplemental Table 1).
Sputum and cough questions. Questionnaires were completed by 
asthma subjects at study entry. CMH was defined using the ATS/
WHO definition of chronic bronchitis, which assesses chronic cough 
and sputum production in the preceding 2 years (16). The specific 
question used was the following: Have you had cough and sputum 
production on most days for at least 3 months a year for at least 2 
consecutive years?
MBRT. Subjects were asked to hold their bronchodilator medi-
cations prior to spirometry testing. Following baseline spirometry, 4 
puffs of albuterol (360 mcg) were administered. Spirometry was then 
repeated 15 minutes later. If the change in FEV1 from the spirometry 
maneuver performed after 4 puffs was greater than 5%, an additional 
2 puffs of albuterol (180 mcg) were then administered and spirometry 
was repeated again 15 minutes later. If the change in FEV1 after 6 puffs 
was greater than 5%, an additional 2 puffs of albuterol were admin-
istered with repeat spirometry after an additional 15 minutes. If the 
change was less than 5% after 4 or 6 puffs of albuterol, the procedure 
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contributions to experimental design. SDM developed the hydro-
gel model for mucus experiments. WWR designed and carried out 
the cysteine and hydrogel assays. EMD, JVF, and BRP conducted 
the data analysis. EMD and JVF prepared the first draft of the man-
uscript, and all authors revised the draft critically for intellectual 
content. All authors have given final approval for the manuscript 
version to be published.
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